ReviewImmunoTargets and therapy2026
Immune Microenvironment of Hair Follicles in Tumor Immunotherapy.
Review in ImmunoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although tumor immunotherapy has shown significant efficacy against solid tumors, it frequently causes cutaneous and follicular adverse events resulting from disruption of the hair follicle immune microenvironment. This microenvironment is maintained through careful regulation by immune cells and cytokine networks to support normal hair cycling. Immune checkpoint inhibitors disturb this balance by activating T cells, promoting macrophage polarization toward pro-inflammatory phenotypes, upregulating inflammatory cytokines such as tumor necrosis factor-alpha, and activating Toll-like receptor/nuclear factor-kappa B signaling pathways, ultimately leading to follicular toxicity including alopecia. Encompass relies mainly on topical corticosteroids and other immunomodulatory agents. A deeper understanding of these mechanisms is essential to identify key regulatory nodes for future targeted interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.